CN113387950A - 一种阿维巴坦钠中间体的精制方法 - Google Patents
一种阿维巴坦钠中间体的精制方法 Download PDFInfo
- Publication number
- CN113387950A CN113387950A CN202010165377.8A CN202010165377A CN113387950A CN 113387950 A CN113387950 A CN 113387950A CN 202010165377 A CN202010165377 A CN 202010165377A CN 113387950 A CN113387950 A CN 113387950A
- Authority
- CN
- China
- Prior art keywords
- avibactam sodium
- sodium intermediate
- impurity
- avibactam
- refining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001496 avibactam sodium Drugs 0.000 title claims abstract description 107
- RTCIKUMODPANKX-JBUOLDKXSA-M avibactam sodium Chemical compound [Na+].NC(=O)[C@@H]1CC[C@H]2N(OS([O-])(=O)=O)C(=O)N1C2 RTCIKUMODPANKX-JBUOLDKXSA-M 0.000 title claims abstract description 107
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000007670 refining Methods 0.000 title claims abstract description 33
- 239000012535 impurity Substances 0.000 claims abstract description 61
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims abstract description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000002904 solvent Substances 0.000 claims abstract description 30
- 239000012043 crude product Substances 0.000 claims abstract description 19
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 29
- 239000000047 product Substances 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 11
- 238000000967 suction filtration Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 238000007142 ring opening reaction Methods 0.000 abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000003321 amplification Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 21
- 229910052708 sodium Inorganic materials 0.000 description 21
- 239000011734 sodium Substances 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 9
- 239000005660 Abamectin Substances 0.000 description 9
- 229950008167 abamectin Drugs 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 102000006635 beta-lactamase Human genes 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000003781 beta lactamase inhibitor Substances 0.000 description 4
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 4
- LVFGWOQWXQLVRO-XJDKXYGGSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound NC(=O)[C@@H]1CC[C@H]2N(OS(O)(=O)=O)C(=O)N1C2.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 LVFGWOQWXQLVRO-XJDKXYGGSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 3
- 229960000484 ceftazidime Drugs 0.000 description 3
- -1 diazabicyclooctanone compound Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 150000003952 β-lactams Chemical group 0.000 description 2
- HYTSWLKLRKLRHK-VXGBXAGGSA-N (2r,5r)-7-oxo-6-phenylmethoxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide Chemical compound C([C@]1(CC[C@@H]2C(N)=O)[H])N2C(=O)N1OCC1=CC=CC=C1 HYTSWLKLRKLRHK-VXGBXAGGSA-N 0.000 description 1
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical compound C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000244269 Peucedanum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940091875 avycaz Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229940036735 ceftaroline Drugs 0.000 description 1
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
时间(分钟) | 流动相A(%) | 流动相B(%) |
0 | 95 | 5 |
15 | 90 | 10 |
50 | 40 | 60 |
55 | 40 | 60 |
56 | 95 | 5 |
60 | 95 | 5 |
序号 | 保留时间(min) | 峰面积(mAU*s) | 峰面积(%) | 杂质编号 |
1 | 2.154 | 1.15566 | 0.0054 | / |
2 | 3.085 | 2.41909 | 0.0113 | 开环杂质B |
3 | 3.455 | 1.34051 | 0.0063 | / |
4 | 5.250 | 2.24009 | 0.0105 | / |
5 | 10.218 | 6.01726 | 0.0281 | / |
6 | 10.863 | 3.04699 | 0.0142 | / |
7 | 16.846 | 21367.63725 | 99.9154 | 阿维巴坦钠中间体1 |
8 | 38.521 | 1.86882 | 0.0087 | / |
序号 | 保留时间(min) | 峰面积(mAU*s) | 峰面积(%) | 杂质编号 |
1 | 3.565 | 2.05008 | 0.0095 | 开环杂质B |
2 | 17.406 | 3.65267 | 0.0169 | 异构体杂质A |
3 | 18.316 | 21651.22337 | 99.9737 | 阿维巴坦钠中间体1 |
序号 | 保留时间(min) | 峰面积(mAU*s) | 峰面积(%) | 杂质编号 |
1 | 3.443 | 3.01199 | 0.0150 | 开环杂质B |
2 | 17.933 | 20021.28143 | 99.9425 | 阿维巴坦钠中间体1 |
3 | 31.785 | 4.01236 | 0.0200 | / |
4 | 37.306 | 4.50376 | 0.0225 | / |
序号 | 保留时间(min) | 峰面积(mAU*s) | 峰面积(%) | 杂质编号 |
1 | 0.990 | 22.59331 | 0.0952 | / |
2 | 3.162 | 85.79259 | 0.3613 | 开环杂质B |
3 | 3.425 | 116.68029 | 0.4914 | / |
4 | 5.155 | 8.95934 | 0.0377 | / |
5 | 10.002 | 10.33919 | 0.0435 | / |
6 | 15.284 | 237.77730 | 1.0015 | 异构体杂质A |
7 | 16.184 | 23075.64815 | 97.1906 | 阿维巴坦钠中间体1 |
8 | 17.061 | 15.84640 | 0.0667 | / |
9 | 25.757 | 15.6683 | 0.0660 | / |
10 | 26.376 | 32.29909 | 0.1360 | / |
11 | 36.798 | 3.50170 | 0.0147 | / |
12 | 37.269 | 10.61468 | 0.0447 | / |
13 | 38.859 | 96.30332 | 0.4056 | / |
14 | 40.242 | 6.66670 | 0.0281 | / |
15 | 41.751 | 3.97886 | 0.0168 | / |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010165377.8A CN113387950A (zh) | 2020-03-11 | 2020-03-11 | 一种阿维巴坦钠中间体的精制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010165377.8A CN113387950A (zh) | 2020-03-11 | 2020-03-11 | 一种阿维巴坦钠中间体的精制方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113387950A true CN113387950A (zh) | 2021-09-14 |
Family
ID=77615331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010165377.8A Pending CN113387950A (zh) | 2020-03-11 | 2020-03-11 | 一种阿维巴坦钠中间体的精制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113387950A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120165533A1 (en) * | 2010-12-22 | 2012-06-28 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
CN105143226A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法 |
CN105753867A (zh) * | 2016-03-24 | 2016-07-13 | 齐鲁制药有限公司 | 一种改进的阿维巴坦钠中间体化合物的制备方法 |
CN107417686A (zh) * | 2017-09-19 | 2017-12-01 | 北京化工大学 | 一种阿维巴坦钠的合成方法 |
CN109400607A (zh) * | 2017-08-16 | 2019-03-01 | 江苏奥赛康药业股份有限公司 | 阿维巴坦中间体及其制备方法 |
CN109678856A (zh) * | 2017-10-18 | 2019-04-26 | 新发药业有限公司 | 一种阿维巴坦中间体的简便制备方法 |
-
2020
- 2020-03-11 CN CN202010165377.8A patent/CN113387950A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120165533A1 (en) * | 2010-12-22 | 2012-06-28 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
CN105143226A (zh) * | 2013-03-08 | 2015-12-09 | 沃克哈特有限公司 | 制备(2s,5r)-2-甲酰胺基-7-氧代-6-磺酰氧基-1,6-二氮杂-双环[3.2.1]辛烷的钠盐的方法 |
CN105753867A (zh) * | 2016-03-24 | 2016-07-13 | 齐鲁制药有限公司 | 一种改进的阿维巴坦钠中间体化合物的制备方法 |
CN109400607A (zh) * | 2017-08-16 | 2019-03-01 | 江苏奥赛康药业股份有限公司 | 阿维巴坦中间体及其制备方法 |
CN107417686A (zh) * | 2017-09-19 | 2017-12-01 | 北京化工大学 | 一种阿维巴坦钠的合成方法 |
CN109678856A (zh) * | 2017-10-18 | 2019-04-26 | 新发药业有限公司 | 一种阿维巴坦中间体的简便制备方法 |
Non-Patent Citations (1)
Title |
---|
赵临襄主编: "《化学制药工艺学》", vol. 4, 中国医药科技出版社, pages: 104 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100497349C (zh) | 一种改进的比阿培南的制备方法 | |
US9090631B2 (en) | Process for purifying cefotiam hydrochloride | |
CN105399754B (zh) | 一种头孢孟多酯钠的制备方法 | |
CN102268019B (zh) | 一种头孢羟氨苄化合物及其制法 | |
CN113365973B (zh) | 苯氧乙酸衍生物及利用其酶法制备青霉素v盐的方法 | |
CN101914098B (zh) | 美罗培南三水合物结晶的制备方法 | |
US8853389B2 (en) | Process for refining cefmetazole sodium | |
CN101891742B (zh) | 美罗培南三水合物结晶的制备方法 | |
CN110452255A (zh) | 头孢曲松钠的晶型及其制备方法 | |
KR100200242B1 (ko) | 클라불란산염의 제조 방법 | |
CN113387950A (zh) | 一种阿维巴坦钠中间体的精制方法 | |
CN105859747B (zh) | 一种适于工业化生产的盐酸头孢吡肟的制备方法 | |
CN110407857B (zh) | 一种头孢硫脒的制备工艺 | |
US8871927B2 (en) | Method for purifying Ceftizoxime sodium | |
EP2604592B1 (en) | A process for the purification of aniracetam by crystallisation from aqueous solutions | |
CN114805639B (zh) | 一种高纯度舒更葡糖钠的制备方法和其应用 | |
CN102898443B (zh) | 高收率超净高纯化头孢地嗪钠的精制方法 | |
CN109734724B (zh) | 一种哌拉西林酸的结晶方法 | |
CN113121536A (zh) | 阿维巴坦钠中间体的精制方法及其制备的阿维巴坦钠中间体 | |
CN114426513A (zh) | 阿维巴坦钠有关物质及其制备方法和用途 | |
CN110974832B (zh) | 一种注射用头孢孟多酯钠的制备方法 | |
CN115707686A (zh) | 一种阿维巴坦钠起始原料的精制方法 | |
CN114249729A (zh) | 一种通过反应结晶制备晶型b阿维巴坦钠的方法 | |
CN106565784B (zh) | 头孢洛林酯二钠盐的纯化方法 | |
CN108727418A (zh) | 一种头孢妥仑匹酯二聚体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220207 Address after: NO.666, Section 2, Xinhua Avenue, cross strait science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province Applicant after: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Applicant after: GUANGXI KELUN PHARMACEUTICAL Co.,Ltd. Address before: 300457 n1505, 15 / F, experimental building of Tianjin International Biomedical Joint Research Institute, No. 220 Dongting Road, economic and Technological Development Zone, Binhai New Area, Tianjin Applicant before: TIANJIN KELUN PHARMACEUTICAL RESEARCH Co.,Ltd. Applicant before: GUANGXI KELUN PHARMACEUTICAL Co.,Ltd. |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |